Regen BioPharma Inc (RGBP)

[cangold122]

$RGBP NEWS TODAY bam


Item 8.01 Other Events.

KCL Therapeutics, Inc. (“KCL”) , a wholly owned subsidiary Regen Biopharma Inc. ( the “Company”), was informed by the United States Patent and Trademark Office ( USPTO) that patent protection shall be granted to KCL with regard to “METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION “( “Invention”).

The Invention pertains to stimulation of immunity to cancer antigens through augmentation of NR2F6 inhibition to augment T-cell activation.

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.
2




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


REGEN BIOPHARMA, INC.

Dated: July 2, 2021 By: /s/ David Koos
David Koos
Chief Executive Officer